Tofacitinib in the treatment of ulceral colitis: real-world clinical practice and prospects
https://doi.org/10.21518/ms2024-344
Abstract
Ulcerative colitis is an immune-inflammatory disease characterized by ulcerative-destructive processes in the colon mucosa. Cytokines, proteins secreted by activated immune cells that affect the activity, differentiation, or proliferation of other cells, play a key role in pathogenesis. Improving the effectiveness of drug therapy for ulcerative colitis is currently associated with the addition of genetically engineered biological drugs (GEBD) and targeted immunosuppressants, Janus kinase inhibitors (tofacitinib), to traditional therapy. Compared with GEBD, tofacitinib has a number of advantages, including its oral administration, rapid onset of action, rapid elimination, and lack of immunogenicity. Tofacitinib was approved by the FDA in 2012 for the treatment of rheumatoid arthritis and in 2017 for the treatment of psoriatic arthritis, and in May 2018 for the treatment of ulcerative colitis. Currently, tofacitinib occupies an important place in the Federal Clinical Guidelines for Ulcerative Colitis of 2024. The Pubmed and Scopus databases were searched for articles on the use of tofacitinib in ulcerative colitis published in the current decade, with an emphasis on publications of the last year and publications not included in previously published domestic reviews. The studies found confirm the effectiveness of tofacitinib in the treatment of moderate to severe ulcerative colitis in patients in various geographic regions. A number of studies have noted the pharmacoeconomic effectiveness of tofacitinib compared to GEBD. Tofacitinib is not presented in the current clinical guidelines for ulcerative colitis for children, but a number of studies indicate the prospects for its integration into pediatric protocols.
About the Author
D. I. Trukhan
Omsk State Medical University
Russian Federation
Russian Federation
Dmitry I. Trukhan, Dr. Sci. (Med.), Associate Professor, Professor of the Department of Polyclinic Therapy and Internal Diseases
12, Lenin St., Omsk, 644043
References
1. Тарасова ЛВ, Трухан ДИ. Болезни кишечника. Клиника, диагностика и лечение. СПб.: СпецЛит; 2022. 222 с.
2. Абдулганиева ДИ, Алексеева ОП, Ачкасов СИ, Бакулин ИГ, Барышева ОЮ, Белоусова ЕА и др. Язвенный колит: клинические рекомендации. М.; 2024. 130 с. Режим доступа: https://cr.minzdrav.gov.ru/recomend/193_2.
3. Grinevich VB, Pershko AM, Volga NB, Ivanyuk ES, Seliverstov PV. Topical issues of therapy for patients with ulcerative colitis. Meditsinskiy Sovet. 2022;17(23):149–154. (In Russ.) https://doi.org/10.21518/ms2023-481.
4. Pantavou K, Yiallourou AI, Piovani D, Evripidou D, Danese S, Peyrin-Biroulet L et al. Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses. United European Gastroenterol J. 2019;7(10):1285–1303. https://doi.org/10.1177/2050640619883566.
5. Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2018;47(4):454–465. https://doi.org/10.1111/apt.14449.
6. Magro F, Estevinho MM. Is tofacitinib a game-changing drug for ulcerative colitis? United European Gastroenterol J. 2020;8(7):755–763. https://doi.org/10.1177/2050640620935732.
7. O’Shea JJ, Laurence A, McInnes IB. Back to the future: oral targeted therapy for RA and other autoimmune diseases. Nat Rev Rheumatol. 2013;9(3):173–182. https://doi.org/10.1038/nrrheum.2013.7.
8. O’Shea JJ, Holland SM, Straudt LM. JAKs and STATs in immunity, immunodefficiency and cancer. N Engl J Med. 2013;368(2):161–170. https://doi.org/10.1056/NEJMra1202117.
9. Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014;57(12):5023–5038. https://doi.org/10.1021/jm401490p.
10. Roskoski RJr. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders. Pharmacol Res. 2022;183:106362. https://doi.org/10.1016/j.phrs.2022.106362.
11. Nasonov EL, Lila AM. Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: New opportunities and prospects. Rheumatology Science and Practice. 2019;57(1):8–16 (In Russ.) https://doi.org/10.14412/1995-4484-2019-8-16.
12. López-Sanromán A, Esplugues JV, Domènech E. Pharmacology and safety of tofacitinib in ulcerative colitis. Gastroenterol Hepatol. 2021;44(1):39–48. https://doi.org/10.1016/j.gastrohep.2020.04.012.
13. Xin P, Xu X, Deng C, Liu S, Wang Y, Zhou X et al. The role of JAK/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol. 2020;80:106210. https://doi.org/10.1016/j.intimp.2020.106210.
14. Villarino AV, Kanno Y, O’Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol. 2017;18(4):374–384. https://doi.org/10.1038/ni.3691.
15. Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs. 2017;77(5):521–546. https://doi.org/10.1007/s40265-017-0701-9.
16. McLornan DP, Pope JE, Gotlib J, Harrison CN. Current and future status of JAK inhibitors. Lancet. 2021;398(10302):803–816. https://doi.org/10.1016/S0140-6736(21)00438-4.
17. Tanaka Y, Luo Y, O’Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: A mechanisms-based approach. Nat Rev Rheumatol. 2022;18(3):133–145. https://doi.org/10.1038/s41584-021- 00726-8.
18. Fortelny N, Farlik M, Fife V, Gorki AD, Lassnig C, Maurer B et al. JAK-STAT signaling maintains homeostasis in T cells and macrophages. Nat Immunol. 2024;25(5):847–859. https://doi.org/10.1038/s41590-024-01804-1.
19. Padda IS, Bhatt R, Parmar M. Tofacitinib. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Available at: https://pubmed.ncbi.nlm.nih.gov/34283514.
20. Nasonov EL. New approaches to pharmacotherapy of rheumatoid arthritis: tofacitinib. Rheumatology Science and Practice. 2014;52(2):209–221. (In Russ.) https://doi.org/10.14412/1995-4484-2014-209-221.
21. Karateyev DЕ. Kinase inhibitors in rheumatoid arthritis: reality and prospects. Meditsinskiy Sovet. 2013;(12):90–96. (In Russ.) https://doi.org/10.21518/2079-701X-2013-12-90-96.
22. Spinelli FR, Meylan F, O’Shea JJ, Gadina M. JAK inhibitors: Ten years after. Eur J Immunol. 2021;51(7):1615–1627. https://doi.org/10.1002/eji.202048922.
23. Liu C, Kieltyka J, Fleischmann R, Gadina M, O’Shea JJ. A decade of JAK inhibitors: What have we learned and what may be the future? Arthritis Rheumatol. 2021;73(12):2166–2178. https://doi.org/10.1002/art.41906.
24. Nasonov EL, Korotaeva TV. Janus kinase inhibitors in immunoinflammatory diseases: 10 years of clinical practice in rheumatology. Rheumatology Science and Practice. 2022;60(2):131–148 (In Russ.) https://doi.org/10.47360/1995-4484-2022-131-148.
25. Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1–s106. https://doi.org/10.1136/gutjnl-2019-318484.
26. Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020;158(5):1450–1461. https://doi.org/10.1053/j.gastro.2020.01.006.
27. Nwaogu A, Bond A, Smith PJ. Guideline review: Tofacitinib for adults with moderately to severely active ulcerative colitis – NICE guidance. Frontline Gastroenterol. 2020;12(2):133–136. https://doi.org/10.1136/flgastro-2020-101502.
28. Amiot A, Bouguen G, Bonnaud G, Bouhnik Y, Hagege H, Peyrin-Biroulet L. French National Consensus Clinical guidelines for the management of IBD study group. Clinical guidelines for the management of inflammatory bowel disease: Update of a French national consensus. Dig Liver Dis. 2021;53(1):35–43. https://doi.org/10.1016/j.dld.2020.10.018.
29. Khalif IL, Shapina MV. Efficacy and safety of tofacitinib in ulcerative colitis (review). Koloproktologia. 2018;(3):94–102. (In Russ.) https://doi.org/10.33878/2073-7556-2018-0-3-94-102.
30. Nasonov EL, Abdulganieva DI, Fairushina IF. The use of Tofacitinib in the treatment of inflammatory bowel disease. Terapevticheskii Arkhiv. 2019;91(2): 8–108. (In Russ.) https://doi.org/10.26442/00403660.2019.02.000155.
31. Mordasova VI, Kopylova DV, Dobrosotskih GV. Management of patients with ulcerative colitis who did not respond to anti-tnf treatment. 2021;17(39): 80–86. (In Russ.) https://doi.org/10.33978/2307-3586-2021-17-39-80-86.
32. Belousova EA, Abdulganieva DI, Alekseeva OP, Bakulin IG, Vasilyeva OV, Veselov AV et al. Experience of tofacitinib using in therapy of ulcerative colitis in real clinical practice. Koloproktologia. 2019;18(4):86–99 (In Russ.) https://doi.org/10.33878/2073-7556-2019-18-4-86-99.
33. Knyazev OV, Shkurko TV, Kagramanova AV, Lishhinskaya AA, Bordin DS, Parfyonov AI. Efficacy and safety of tofacitinib for moderate and severe ulcerative colitis in real clinical practice: an open observational prospective study. Farmateka. 2020;27(2):38–44. (In Russ.) https://doi.org/10.18565/pharmateca.2020.2.38-44.
34. Podolskaya DV, Shapina MV, Baranova TA, Tishaeva IA, Alexandrov AL, Knyazev OV, Nanaeva BA. Efficacy of tofacitinib as a "rescue therapy" in patients with severe ulcerative colitis. Koloproktologia. 2021;20(3):43–50. (In Russ.) https://doi.org/10.33878/2073-7556-2021-20-3-43-50.
35. Knyazev OV, Kagramanova AV, Lishchinskaya AA, Li IA, Podolskaya DV, Shkurko TV et al. Efficacy and safety of tofacitinib in moderate and severe ulcerative colitis in real clinical practice: three years of observation. Meditsinskiy Sovet. 2021;(15):20–29. (In Russ.) https://doi.org/10.21518/2079-701X-2021-15-20-29.
36. Taxonera C, Olivares D, Alba C. Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With MetaAnalysis. Inflamm Bowel Dis. 2022;28(1):32–40. https://doi.org/10.1093/ibd/izab011.
37. Macaluso FS, Maida M, Ventimiglia M, Orlando A. Effectiveness and safety of tofacitinib for the treatment of ulcerative colitis: A single-arm meta-analysis of observational studies. Dig Liver Dis. 2022;54(2):183–191. https://doi.org/10.1016/j.dld.2021.04.018.
38. Honap S, Agorogianni A, Colwill MJ, Mehta SK, Donovan F, Pollok R et al. JAK inhibitors for inflammatory bowel disease: recent advances. Frontline Gastroenterol. 2023;15(1):59–69. https://doi.org/10.1136/flgastro-2023-102400.
39. Banerjee R, Sharma V, Patel R, Jena A, Pal P, Raghunathan N et al. Tofacitinib use in ulcerative colitis: An expert consensus for day-to-day clinical practice. Indian J Gastroenterol. 2024;43(1):22–35. https://doi.org/10.1007/s12664-023-01507-9.
40. Herfarth HH, Afzali A, Fischer M, Hudesman D, Abdalla M, McCabe R et al. Clinical Long-Term Outcomes of Patient-Reported Outcomes in the Prospective Real-World Tofacitinib Response in Ulcerative Colitis Registry. Clin Transl Gastroenterol. 2024;15(3):e00669. https://doi.org/10.14309/ctg.0000000000000669.
41. Resál T, Bacsur P, Keresztes C, Bálint A, Bor R, Fábián A et al. Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study. Inflamm Bowel Dis. 2024;30(5):768–779. https://doi.org/10.1093/ibd/izad135.
42. Giri S, Bhrugumalla S, Kamuni A, Mishra D, Pati GK, Agrawal D et al. Upfront tofacitinib in patients with biological-naïve ulcerative colitis – An Indian multicentric experience. Indian J Gastroenterol. 2024;43(1):237–243. https://doi.org/10.1007/s12664-023-01434-9.
43. Singh A, Goyal MK, Midha V, Mahajan R, Kaur K, Gupta YK et al. Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): A Randomized Controlled Trial. Am J Gastroenterol. 2024;119(7):1365–1372. https://doi.org/10.14309/ajg.0000000000002635.
44. Singh A, Midha V, Kaur K, Mahajan R, Singh D, Kaur R et al. Tofacitinib Versus Oral Prednisolone for Induction of Remission in Moderately Active Ulcerative Colitis: A Prospective, Open-Label, Randomized, Pilot Study. J Crohns Colitis. 2024;18(2):300–307. https://doi.org/10.1093/ecco-jcc/jjad153.
45. Khan N, Sundararajan R, Patel M, Trivedi C, Yang YX. Effectiveness of Tofacitinib in Patients With Ulcerative Colitis: A Nationwide Veterans Administration Cohort Study. Am J Gastroenterol. 2024;119(8):1632–1635. https://doi.org/10.14309/ajg.0000000000002761.
46. Yu A, Ha NB, Shi B, Cheng YW, Mahadevan U, Beck KR. Real-World Experience With Tofacitinib Dose De-Escalation in Patients With Moderate and Severe Ulcerative Colitis. Clin Gastroenterol Hepatol. 2023;21(12):3115–3124.e3. https://doi.org/10.1016/j.cgh.2023.05.001.
47. Ollech JE, Eran-Banai H, Goren I, Sharar Fischler T, Avni-Biron I, Snir Y et al. Tofacitinib is an effective treatment for moderate to severe ulcerative colitis, and intestinal ultrasound can discriminate response from non-response: a pragmatic prospective real-world study. Ann Med. 2024;56(1):2358183. https://doi.org/10.1080/07853890.2024.2358183.
48. Molander P, Kosunen M, Eronen H, Tillonen J, Käräjämäki A, Heikkinen M et al. Tofacitinib real-world experience in ulcerative colitis in Finland (FinTofUC): a retrospective non-interventional multicenter patient chart data study. Scand J Gastroenterol. 2024;59(4):425–432. https://doi.org/10.1080/00365521.2023.2298361.
49. Kojima K, Watanabe K, Kawai M, Yagi S, Kaku K, Ikenouchi M et al. Realworld efficacy and safety of tofacitinib treatment in Asian patients with ulcerative colitis. World J Gastroenterol. 2024;30(13):1871–1886. https://doi.org/10.3748/wjg.v30.i13.1871.
50. Singh A, Mahajan R, Midha V, Kaur K, Singh D, Kaur R et al. Effectiveness of Tofacitinib in Ulcerative Proctitis Compared to Left Sided Colitis and Pancolitis. Dig Dis Sci. 2024;69(4):1389–1402. https://doi.org/10.1007/s10620-024-08276-1.
51. Uzzan M, Nachury M, Nuzzo A, Amiot A, Caron B, Benezech A et al. Tofacitinib for Patients with Anti-TNF Refractory Ulcerative Proctitis: A Multicentre Cohort Study from the GETAID. J Crohns Colitis. 2024;18(3):424–430. https://doi.org/10.1093/ecco-jcc/jjad169.
52. Vieujean S, Laharie D, Buisson A, Roblin X, Fumery M, Nancey S et al. Histological healing induced by tofacitinib in ulcerative colitis: A multicentre study. Dig Liver Dis. 2024;56(4):613–621. https://doi.org/10.1016/j.dld.2023.11.022.
53. Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis. Gastroenterology. 2020;158(6):1554–1573.e12. https://doi.org/10.1053/j.gastro.2020.01.001.
54. Panés J, D’Haens GR, Sands BE, Ng SC, Lawendy N, Kulisek N et al. Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure. United European Gastroenterol J. 2024;12(6):793–801. https://doi.org/10.1002/ueg2.12584.
55. Beaugerie L. Safety of tofacitinib in IBD: A tricky puzzle. United European Gastroenterol J. 2024;12(6)658–659. https://doi.org/10.1002/ueg2.12587.
56. Schreiber S, Rubin DT, Ng SC, Peyrin-Biroulet L, Danese S, Modesto I et al. Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme. J Crohns Colitis. 2023;17(11):1761–1770. https://doi.org/10.1093/ecco-jcc/jjad104.
57. Macaluso FS, D’Antonio E, Fries W, Viola A, Ksissa O, Cappello M et al. Safety and effectiveness of tofacitinib in ulcerative colitis: Data from TOFA-UC, a SN-IBD studу. Dig Liver Dis. 2024;56(1):15–20. https://doi.org/10.1016/j.dld.2023.08.061.
58. Carvalhas Gabrielli AM, Ferretti F, Monico CM, Tombetti E, Maconi G, Romeo S et al. Effect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study. Dig Dis Sci. 2024;69(5):1785–1792. https://doi.org/10.1007/s10620-024-08394-w.
59. Dragoni G, Innocenti T, Amiot A, Castiglione F, Melotti L, Festa S et al. Rates of Adverse Events in Patients With Ulcerative Colitis Undergoing Colectomy During Treatment With Tofacitinib vs Biologics: A Multicenter Observational Study. Am J Gastroenterol. 2024;119(8):1525–1535. https://doi.org/10.14309/ajg.0000000000002676.
60. Chichasova NV. Tofacitinib: efficiency and safety in long-term use. Meditsinskiy Sovet. 2019;(1):64–71. (In Russ.) https://doi.org/10.21518/2079-701X-2019-1-64-71.
61. Kobayashi T, Hoshi M, Yuasa A, Arai S, Ikeda M, Matsuda H et al. CostEffectiveness Analysis of Tofacitinib Compared with Biologics in BiologicNaïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan. Pharmacoeconomics. 2023;41(5):589–604. https://doi.org/10.1007/s40273-023-01254-x.
62. Taxonera C, de Andrés-Nogales F, García-López S, Sánchez-Guerrero A, Menchén B, Peral C et al. Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain. Expert Rev Pharmacoecon Outcomes Res. 2022;22(1):73–83. https://doi.org/10.1080/14737167.2021.1880324.
63. Vellopoulou K, Stefanou G, Tzanetakos C, Boubouchairopoulou N, Nakou M, Gourzoulidis G, Kourlaba G. Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece. Eur J Gastroenterol Hepatol. 2021;33(3):325–333. https://doi.org/10.1097/MEG.0000000000001916.
64. Баранов АА, Намазова-Баранова ЛС, Разумовский АЮ, Хавкин АИ, Бельмер СВ, Боровик ТЭ и др. Язвенный колит: клинические рекомендации. М.; 2021. Режим доступа: https://cr.minzdrav.gov.ru/recomend/391_2.
65. Ledder O, Dolinger M, Dubinsky MC, Stein R, Vellanki S, Buckuk R et al. Tofacitinib in Pediatric Ulcerative Colitis: A Retrospective Multicenter Experience. Inflamm Bowel Dis. 2024:izae112. https://doi.org/10.1093/ibd/izae112.
66. Parra-Izquierdo V, Frías-Ordoñez JS, Cuadros C, Vargas M, Vera Chamorro JF, Romero Sanchez C, Flórez-Sarmiento C. Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombian pediatric patients: Real world experience. Gastroenterol Hepatol. 2024;47(6):574–581. https://doi.org/10.1016/j.gastrohep.2023.09.013.
67. Costaguta GA, Girard C, Groleau V, Grzywacz K, Dirks MH, Deslandres C. The Role of Tofacitinib in the Treatment of Acute Severe Colitis in Children. J Can Assoc Gastroenterol. 2023;7(2):196–203. https://doi.org/10.1093/jcag/gwad042.
68. Panés J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D’Haens G et al. Tofacitinib for induction and maintenance therapy of Crohn’s disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017;66(6):1049–1059. https://doi.org/10.1136/gutjnl-2016-312735.
69. Fenster M, Alayo QA, Khatiwada A, Wang W, Dimopoulos C, Gutierrez A et al. Real-World Effectiveness and Safety of Tofacitinib in Crohn’s Disease and IBD-U: A Multicenter Study From the TROPIC Consortium. Clin Gastroenterol Hepatol. 2021;19(10):2207–2209.e3. https://doi.org/10.1016/j.cgh.2020.10.025.
70. Biemans VB, Verstockt B. Tofacitinib, two-faced Janus in ulcerative colitis and Crohn’s disease? United European Gastroenterol J. 2020;8(7):753–754. https://doi.org/10.1177/2050640620942641.
71. Ortenberg EA. Janus kinase inhibitors and COVID-19 – place in pharmacotherapy algorithms. Lekarstvennyi Vestnik. 2021;83(3):21–27. (In Russ.) Available at: https://www.volgmed.ru/uploads/journals/articles/1632749394-drugs-bulletin-2021-3-3968.pdf.
72. Patoulias D, Doumas M, Papadopoulos C, Karagiannis A. Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials. Clin Rheumatol. 2021;40(11):4671–4674. https://doi.org/10.1007/s10067-021-05884-4.
73. ТTrukhan DI. Originals and generics: Rebooting in the light of the economic crisis. Spravochnik Poliklinicheskogo Vracha. 2012;(4):32–36. (In Russ.) Available at: https://www.indap.info/assets/files/indap2.pdf.
74. Krämer I. Biosimilars. Ther Umsch. 2011;68(11):659–666. https://doi.org/10.1024/0040-5930/a000227.
75. Danese S, Fiorino G, Raine T, Ferrante М, Kemp К, Kierkus J et al. ECCO position statement on the use of biosimilars for inflammatory bowel disease-an update. J Crohns Colitis. 2017;11(1):26–34. https://doi.org/10.1093/ecco-jcc/jjw198.
76. Cohen H, Blauvelt A, Rifkin RM, Danese S, Gokhale SB, Woollett G. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs. 2018;78(4):463–478. https://doi.org/10.1007/s40265-018-0881-y.
77. Crommelin DJ, Shah VP, Klebovich I, McNeil SE, Weinstein V, Flühmann B et al. The similarity question for biologicals and non-biological complex drugs. Eur J Pharm Sci. 2015;76:10–17. https://doi.org/10.1016/j.ejps.2015.04.010.
78. Bashkova IB, Madyanov IV. Tofacitinib as a means of optimizing the treatment of rheumatoid arthritis at the outpatient stage (clinical cases). Meditsinskiy Sovet. 2024;18(3):139–147. (In Russ.) https://doi.org/10.21518/ms2024-083.
Review
For citations:
Trukhan DI. Tofacitinib in the treatment of ulceral colitis: real-world clinical practice and prospects. Meditsinskiy sovet = Medical Council. 2024;(15):200–208. (In Russ.) https://doi.org/10.21518/ms2024-344
Views:
158
Email this article 